Zotsatira Zabwino Zatsopano Zochizira Psoriatic Arthritis

ACELYRIN, INC., Affibody AB, ndi Inmagene Biopharmaceuticals Co., Ltd., lero alengeza kuti kuyesa kwachipatala kwa milungu 16, padziko lonse lapansi, Phase 2 ya izokibep mwa odwala 135 omwe ali ndi nyamakazi ya psoriatic (PsA) adakwaniritsa mapeto ake a ACR50. Izokibep inapezanso mapeto achiwiri, kuphatikizapo kuyankha kwa PASI, kusintha kwa ma LEED a enthesitis, ndi kusintha kwa moyo pa chida chovomerezeka cha PsA-specific, funso la Psoriatic Impact of Disease (PsAID).   

Mayesero achipatala a Phase 2 osasinthika, osawona, osawona, olamulidwa ndi placebo, adayesa chitetezo ndi mphamvu za izokibep 80 mg milungu iwiri iliyonse (Q2W) kapena 40 mg Q2W, motsutsana ndi placebo Q2W, mwa odwala akuluakulu omwe ali ndi PsA yogwira ntchito. Mapeto oyambirira a ACR50 ndi mapeto achiwiri a mayankho a PASI anakwaniritsidwa ndipo anali pamwamba pa mayankho osiyanasiyana, poyerekeza ndi zomwe zanenedwa za mankhwala ena ovomerezeka kapena omwe akupanga PsA. Chiwerengero cha odwala omwe ali ndi vuto la enthesitis chikuwoneka kuti chikusiyana. Kusintha kwatanthauzo m'moyo wamoyo wokhudzana ndi matenda kunapezedwa ndi muyeso wofotokozedwa ndi odwala, PsAID. Palibe zatsopano zachitetezo zomwe zidadziwika.

"Deta yabwino yopangidwa muyeso ya Gawo 2 imathandizira malingaliro athu kuti potency yayikulu ndi kukula kochepa kwa izokibep kumapangitsa kuti pakhale kuwonekera kwakukulu, motero, kuchita bwino kwambiri. Kulowetsedwa kwamankhwala muzambiri zowundana bwino, zopanda vascularized entheseal zitha kugwirizana ndi kuchepa kwakukulu komwe kumawonedwa ndi chithandizo cha izokibep," atero a Paul Peloso, MD, wamkulu wachipatala (CMO) wa ACELYRIN.

"Kupweteka kotsalira kwa entheseal kumalumikizidwa ndi matenda oopsa komanso moyo wosauka. Ndizosangalatsa kuwona kusintha kwabwino kwa enthesitis komanso moyo wabwino wa odwala," adawonjezera.

“Psoriatic nyamakazi ndi matenda otupa opweteka komanso ofooketsa a m’malo olumikizirana mafupa, khungu, ndi misomali, ndipo amathanso kukhudza msana. Ndife okondwa kuti mayeso a Gawo 2 akuwonetsa kuthekera kwa izokibep kuti apereke chithandizo chosiyana m'derali la kufunikira kosakwanira," adatero Prof. Nikolai Brun, MD, PhD, CMO wa Affibody. "Chofunika kwambiri, mwayi udakali woti mupitirize kufufuza zowonetseratu kuti muthe kuyankha bwino ndikupereka izokibep ngati jekeseni imodzi ya SC."

Shao-Lee Lin, MD, PhD, woyambitsa nawo komanso CEO wa ACELYRIN, adati, "Zida izi zikuwonetsa chidaliro chathu munjira yomwe idalengezedwa kale yowunika kuthekera kwa zoletsa za IL-17A pakusintha kosinthika m'maiko ambiri a matenda."

"Deta ya PsA P2 ili ndi zotsatira zabwino makamaka za axial spondyloarthritis (AxSpA) ndi psoriasis (PsO), zomwe zimakhudzidwa ndi mayankho a enthesitis ndi PASI. Kuyeza kwapamwamba (160mg QW) ndi Q2W dosing ya izokibep kudzaphunziridwa mu phunziro lofunika kwambiri la PsA P2b/3 ngati sitepe yotsatira yopititsa patsogolo pulogalamuyi," anawonjezera.

David Bejker, CEO wa Affibody, adati, "Zotsatira za phunziroli ndizofunikira posonyeza mwayi wopanga mankhwala opangidwa bwino kwambiri pogwiritsa ntchito teknoloji ya Affibody®."

Tsatanetsatane wa data ya mayeso a PsA Phase 2 idzagawidwa ndi chiwonetsero chazithunzi ku European Alliance of Associations for Rheumatology (EULAR) Congress ku Copenhagen pa June 3, 2022, nthawi ya 11:05AM CET.

ACELYRIN ili ndi ufulu wadziko lonse ku izokibep kupatula ufulu wachitukuko ndi malonda ndi Inmagene m'mayiko osankhidwa a Asia, kuphatikizapo China, Hong Kong, South Korea, ndi Taiwan, kuphatikizapo Japan. Affibody ali ndi ufulu wochita malonda m'maiko a Nordic.